Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis.

Slides:

Advertisements

Similar presentations

DNA content flow cytometric histograms of propidium iodide–stained A549 cells. DNA content flow cytometric histograms of propidium iodide–stained A549.

Advertisements

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

PARPi combinations against HR-proficient tumors.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Effects of SC144 on in vivo ovarian tumor.

ROS induction and ATR inhibition synergize in inducing multiple myeloma (MM) cell death. ROS induction and ATR inhibition synergize in inducing multiple.

Regorafenib inhibits angiogenesis and induces apoptosis.

Expression of p110γ isoform in macrophages promotes tumor growth and angiogenesis. Expression of p110γ isoform in macrophages promotes tumor growth and.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Antitumor activity of bevacizumab in PDX models was not correlated with the ratio of human and mouse VEGF-A of the models. Antitumor activity of bevacizumab.

Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

TFAP2A knockdown inhibits tumor growth in vivo.

Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.

Coinjection of CAFs induces a collagen cross-link switch in tumor stroma. Coinjection of CAFs induces a collagen cross-link switch in tumor stroma. A,

Effect of HA on hematopoietic recovery in tumor-bearing mice.

Identification of NSC as a FADD-kinase inhibitor.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

CAT displays very high in vivo stability as exemplified by a rat PK study. CAT displays very high in vivo stability as exemplified by a rat.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

In vivo thrombosis of tumor vasculature.

Vascular staining in CWR22R xenograft tumors.

Anti-Flk-1 mAb treatment reduces vessel density in tumors.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

Expression of CRC stem cell markers and L1 in CRC cells.

Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced cytotoxicity in MCF-7 cells. Bcl-2 and caspase inhibition fails to inhibit BAMLET-induced.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

GA reduces the growth of Caki-1 tumor xenografts.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

Bone marrow stroma partially protects multiple myeloma and AML cell lines from tipifarnib- and bortezomib-induced cell death. 8226/S myeloma cells were.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

Tumor and serum levels of murine IL-12.

ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.

Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Micrographs.

Xenograft regrowth studies.

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Influenza vaccine enhances NK cell function through IFN-α.

A, tumor growth studies in H1975 tumor–bearing mice.

miR-100 suppresses bladder cancer cell growth in vitro and in vivo.

Number of identical D-loop DNA clones detected in 10 DNA clones derived from liver tumor tissues. Number of identical D-loop DNA clones detected in 10.

CRA inhibits the growth of human tumor xenografts in vivo.

Inhibitions of the proteasome and aggresome pathways by bortezomib and DACi. Unfolded and/or misfolded proteins are targeted by ubiquitin for degradation.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

HMQ1611 inhibited breast tumor growth in mice.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

Systemic reovirus treatment targets disseminated human myeloma in vivo

Identification of compounds that enhance TMZ cytotoxicity in melanoma cells by screening the Spectrum Collection library. Identification of compounds that.

CPI-444 enhances T-cell activation in MC38 tumors.

VEGF165 stimulates migration of HMVECs

A, VEGFR2 staining in the tumor rim and center.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

Empty basement membrane sleeves and endothelial sprouts.

Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.

Volume 15, Issue 2, Pages (February 2007)

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated.

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

miR-181a knockdown inhibits VEGF and MMP1 secretion in vitro.

Loss of NQO1 expression inhibits invasion of NSCLC

WEE1 inhibition followed by TRAIL treatment results in apoptotic cell death in MB231 cells. WEE1 inhibition followed by TRAIL treatment results in apoptotic.

Presentation transcript:

Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. A, left, immunohistochemical analysis of the microvessel density marker CD31 in multiple myeloma tumor samples. Samples from three animals in each treatment group were analyzed. Representative data. A, right, quantification of CD31+ microvessel density as described in Materials and Methods. Mean ± SE of triplicate. B, left, immunohistochemical analysis of VEGF in multiple myeloma tumor samples revealed that curcumin alone and in combination with bortezomib suppresses angiogenesis. Samples from three animals in each treatment group were analyzed. Representative data. B, right, quantification of VEGF as described in Materials and Methods. Mean ± SE of triplicate. Bokyung Sung et al. Mol Cancer Ther 2009;8:959-970 ©2009 by American Association for Cancer Research